Parkinson's Disease (PD)Gait DisordersTranscranial Magnetic StimulationSpinal Cord Stimulation
Investigational drug(s) / intervention(s)
Repetitive Transcranial Magnetic StimulationCervical Trans-spinal Magnetic StimulationThoracic Trans-spinal Magnetic Stimulation
Repetitive Transcranial Magnetic Stimulation: Repetitive transcranial magnetic stimulation applied over the primary motor cortex using standardized stimulation parameters.
Cervical Trans-spinal Magnetic Stimulation: Trans-spinal magnetic stimulation applied at the cervical level using standardized stimulation parameters.
Thoracic Trans-spinal Magnetic Stimulation: Trans-spinal magnetic stimulation applied at the thoracic level using standardized stimulation parameters.
Study summary
This randomized clinical trial aims to compare the effects of two different trans-spinal magnetic stimulation (tsMS) application sites, cervical versus thoracic, when combined with repetitive transcranial magnetic stimulation (rTMS), on functional mobility in individuals with Parkinson's disease (PD). Participants diagnosed with PD will be randomized into two intervention groups (rTMS + cervical tsMS or rTMS + thoracic tsMS) and will undergo 10 treatment sessions. Outcomes will include functional mobility, gait speed, motor function, freeing of gait, balance, quality of life, global perceived improvement and adverse events. The study is expected to identify the most effective tsMS application site to enhance mobility and motor outcomes in PD, contributing to the optimization and standardization of tsMS protocols as an adjunct therapy.
Eligibility
Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: (i) a clinical diagnosis of Parkinson's disease confirmed by a neurologist; (ii) stable dopaminergic pharmacological treatment for at least three months; (iii) age 40 years or older; (iv) disease stage between 2.5 and 3 on the modified Hoehn and Yahr scale; (v) (v) gait impairment, defined as the occurrence of at least one freezing of gait episode per week.
\-
Exclusion Criteria:
(i) other neurological disorders, orthostatic hypotension, vestibular, musculoskeletal, or visual impairments that could compromise performance on the proposed assessments; (ii) other osteomuscular conditions affecting the lower limbs that interfere with mobility and functional performance; (iii) a Montreal Cognitive Assessment (MoCA) score lower than 21 points; (iv) prior surgical procedures for Parkinson's disease; or (v) contraindications to magnetic stimulation techniques, including a history of seizures or the presence of metallic implants in the neck or spinal region.
Primary outcome measure(s)
Functional Mobility (Timed Up and Go Test) — Baseline, at Day 10 (end of intervention), and at 15 and 30 days post-intervention Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants are instructed to stand up from a chair, walk 3 meters at a fast but safe speed, turn around, return, and sit down. The outcome is the time to complete the task (in seconds), with lower values indicating better functional mobility.
Trial sites (1)
Facility
City
Region
Status
Universidade Federal de Pernambuco
Recife
Pernambuco
Recruiting
More Universidade Federal de Pernambuco trials in Brazil
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
